Immunotherapy and chemo pill after standard treatment for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether giving an immunotherapy drug (sintilimab) combined with a pill chemotherapy (capecitabine) after standard treatment can help prevent nasopharyngeal cancer from coming back in people with high-risk stages. You must have already completed standard chemo-immunotherapy and radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a specific later stage of nasopharyngeal cancer (T4N1M0 or T1-4N2-3M0).
- You have already completed the standard first treatment: chemotherapy (gemcitabine + cisplatin), immunotherapy (sintilimab), and radiation therapy (33 sessions).
- You do not have active autoimmune diseases (except well-controlled type 1 diabetes or hypothyroidism).
- Your blood counts and liver/kidney function are within safe limits (checked by a blood test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiation works better than chemoradiation alone for people with a specific type of advanced nasopharyngeal cancer. It aims to shrink tumors before surgery and prevent cancer from coming back.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial compares two options—a type of immunotherapy or a chemotherapy pill (capecitabine)—as maintenance treatment after standard chemoradiation for high-risk nasopharyngeal cancer. It aims to see which helps prevent the cancer from coming back.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.